FOLH1 and central nervous system cancer: In patients suffering from glioma, limited available data suggest that it may prove highly accurate for the purpose of detecting tumor recurrence, with the absence of PSMA-targeting PET ligand uptake in the normal brain parenchyma and rupture of the blood–brain barrier allowing facile accessibility of the ligand to its target resulting in high tumor-to-background ratios and straightforward visualization of the recurrence.